Oral Anticoagulant Therapy for Patients with New-onset Atrial Fibrillation Following Acute Myocardial Infarction: A Narrative Review

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Nov 21

PMID 36407466

Authors

Shenglong Yu

Chenxi Li

Huizhuang Guo

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the advantages and disadvantages of anticoagulant therapy and provide a piece of information on anti-thrombotic treatment strategies for patients with new-onset atrial fibrillation (NOAF) and acute myocardial infarction (AMI).

Methods: Literature from PubMed and Google scholar were screened until August 2022. Studies assessing oral anticoagulant (OAC) treatments for NOAF in patients with AMI were evaluated for inclusion.

Results: Three retrospective cohort studies were included. In the study performed by Madsen et al., patients with previously diagnosed AMI with or without NOAF were followed up for 5.8 years. About 38% of NOAF patients with anticoagulant therapies, which could reduce long-term mortality [adjusted hazard ratio (HR): 0.69; 95% confidence interval (CI): 0.47-1.00]. Hofer et al. performed a single-center cohort study containing 1,372 patients with AMI with an 8.6-year follow-up period. Dual anti-thrombotic therapy (DAT) did not show the effect on the survival in NOAF (adjusted HR: 0.97; 95% CI: 0.65-1.57), while triple antithrombotic therapy (TAT) could reduce long-term cardiovascular mortality (adjusted HR: 0.86; 95% CI: 0.45-0.92). Petersen et al. also did a cohort study with 1-year follow-up duration. It showed that anticoagulant therapies demonstrated positive results (HR: 0.78; 95% CI: 0.41-1.47).

Conclusion: Recent studies have shown that anticoagulant therapy in AMI-NOAF patients can obviously reduce the mortality of AMI-NOAF patients, especially OAC therapy. Further clinical trials could confirm these findings.

References

Yoshizaki T, Umetani K, Ino Y, Takahashi S, Nakamura M, Seto T . Activated inflammation is related to the incidence of atrial fibrillation in patients with acute myocardial infarction. Intern Med. 2012; 51(12):1467-71. DOI: 10.2169/internalmedicine.51.7312. View

Luo J, Li H, Qin X, Liu B, Zhao J, Maihe G . Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: A systematic review and meta-analysis. Int J Cardiol. 2018; 265:125-131. DOI: 10.1016/j.ijcard.2018.04.096. View

Topaz G, Flint N, Steinvil A, Finkelstein A, Banai S, Keren G . Long term prognosis of atrial fibrillation in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Int J Cardiol. 2017; 240:228-233. DOI: 10.1016/j.ijcard.2017.03.060. View

Vaduganathan M, Harrington R, Stone G, Steg G, Gibson C, Hamm C . Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2017; 13(15):e1841-e1849. DOI: 10.4244/EIJ-D-17-00723. View

Valgimigli M, Bueno H, Byrne R, Collet J, Costa F, Jeppsson A . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the.... Eur Heart J. 2017; 39(3):213-260. DOI: 10.1093/eurheartj/ehx419. View

Gorog D, Geisler T . Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. Thromb Haemost. 2020; 120(4):565-578. DOI: 10.1055/s-0040-1702920. View

Pedersen O, BAGGER H, Kober L, Torp-Pedersen C . The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J. 1999; 20(10):748-54. DOI: 10.1053/euhj.1998.1352. View

Chugh S, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin E . Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2013; 129(8):837-47. PMC: 4151302. DOI: 10.1161/CIRCULATIONAHA.113.005119. View

Pesarini G, Ariotti S, Ribichini F . Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions. Interv Cardiol. 2018; 9(2):94-101. PMC: 5808560. DOI: 10.15420/icr.2011.9.2.94. View

10.

van Rein N, Heide-Jorgensen U, Lijfering W, Dekkers O, Sorensen H, Cannegieter S . Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2018; 139(6):775-786. DOI: 10.1161/CIRCULATIONAHA.118.036248. View

11.

Schmitt J, Duray G, Gersh B, Hohnloser S . Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2008; 30(9):1038-45. DOI: 10.1093/eurheartj/ehn579. View

12.

Soliman E, Lopez F, ONeal W, Chen L, Bengtson L, Zhang Z . Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015; 131(21):1843-50. PMC: 4447576. DOI: 10.1161/CIRCULATIONAHA.114.014145. View

13.

Levine G, Bates E, Bittl J, Brindis R, Fihn S, Fleisher L . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update.... Circulation. 2016; 134(10):e123-55. DOI: 10.1161/CIR.0000000000000404. View

14.

Karabag Y, Rencuzogullari I, Cagdas M, Karakoyun S, Yesin M, Uluganyan M . Association between BNP levels and new-onset atrial fibrillation : A propensity score approach. Herz. 2017; 43(6):548-554. DOI: 10.1007/s00059-017-4598-6. View

15.

Valgimigli M, Costa F, Lokhnygina Y, Clare R, Wallentin L, Moliterno D . Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017; 38(11):804-810. PMC: 5837470. DOI: 10.1093/eurheartj/ehw525. View

16.

Hofer F, Kazem N, Hammer A, El-Hamid F, Koller L, Niessner A . Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies. Eur Heart J Cardiovasc Pharmacother. 2020; 7(3):189-195. DOI: 10.1093/ehjcvp/pvaa027. View

17.

Lee J, Kim S, Lee W, Cho Y, Kang S, Park J . New-onset paroxysmal atrial fibrillation in acute myocardial infarction: increased risk of stroke. BMJ Open. 2020; 10(9):e039600. PMC: 7513639. DOI: 10.1136/bmjopen-2020-039600. View

18.

Alasady M, Abhayaratna W, Leong D, Lim H, Abed H, Brooks A . Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011; 8(7):955-60. DOI: 10.1016/j.hrthm.2011.02.016. View

19.

Sorensen R, Hansen M, Abildstrom S, Hvelplund A, Andersson C, Jorgensen C . Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374(9706):1967-74. DOI: 10.1016/S0140-6736(09)61751-7. View

20.

Naghavi M, Libby P, Falk E, Casscells S, Litovsky S, Rumberger J . From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108(14):1664-72. DOI: 10.1161/01.CIR.0000087480.94275.97. View